Spots Global Cancer Trial Database for SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Official Title: A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Study ID: NCT05642780
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hunan Cancer Hospital, Changsha, , China
Fudan University Shanghai Cancer Center, Shanghai, , China
Fudan University Shanghai Cancer Center, Shanghai, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
